Bridgebio Pharma, INC Schedule 13D activist filings

Viking Global Investors LP and affiliated entities have reported significant sales of BridgeBio Pharma, Inc. common stock, reducing their beneficial ownership below 5%.

Viking Global Investors LP and affiliated entities have filed an amendment to their Schedule 13D, reporting a change in beneficial ownership of BridgeBio Pharma, Inc. common stock.

Viking Global Investors and its affiliates have reduced their beneficial ownership in BridgeBio Pharma, Inc. to 8.2% through recent stock sales.

Viking Global Investors LP and affiliates updated their beneficial ownership in BridgeBio Pharma, Inc., reporting a net reduction in shares since July 1, 2025.

Viking Global Investors and its affiliated entities have filed an Amendment No. 7 to their Schedule 13D, reporting a reduced beneficial ownership of 9.8% in BridgeBio Pharma, Inc. following significant net selling of shares.

KKR Genetic Disorder L.P. has filed an amendment to its Schedule 13D, disclosing the sale of 6 million shares of BridgeBio Pharma, Inc. common stock for $34.20 per share, reducing its beneficial ownership to 7.0%.

Viking Global Investors LP and its affiliates filed Amendment No. 6 to their Schedule 13D for BridgeBio Pharma, Inc., primarily to update the title of the authorized contact person, while maintaining a significant beneficial ownership of 11.7%.

KKR Genetic Disorder L.P., a key investment entity of Kohlberg Kravis Roberts & Co. L.P., has significantly reduced its beneficial ownership in BridgeBio Pharma, Inc. by selling 6 million shares.

Viking Global Investors and its affiliated entities have significantly reduced their beneficial ownership in BridgeBio Pharma, Inc., selling over 3 million shares.